Navigation Links
Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Date:8/20/2007

PRINCETON, N.J., Aug. 20 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg strengths. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drugs as follows: 10 mg/325 mg Norco Tablets of Watson Pharmaceuticals Inc., 5 mg/500 mg Vicodin Tablets, and 7.5 mg/750 mg Vicodin ES Tablets both of Abbott Laboratories, and 10 mg/500 mg Lortab Tablets of UCB Inc. Total annual market sales for Hydrocodone Bitartrate and Acetaminophen Tablets were $390.6 million (IMS - MAT: June 2007).

"Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the relief of moderate to moderately severe pain, and Ranbaxy is pleased to receive final FDA approval for multiple strengths of this product. These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period to all classes of trade," according to Jim Meehan, Vice President of Sales and Marketing for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several a
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Major Manufacturer of Unapproved and Adulterated Drugs
6. FDA Advises Manufacturers to Test Glycerin for Possible Contamination
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
9. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
10. Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data
11. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...mab Program to be Discontinued and Headcount to be... its Portfolio Review; Zanolimumab Program to be ...r of Employees, COP...b A/S (OMX: GEN),announced today that it is discon... In addition, as a result of a portfolio review an...
(Date:10/8/2008)...gs Confirm Potency of Poly-ICR as Vaccine Adjuvant...nta Biopharmaceuticals,Corporation (TSX: NVN) toda... using its proprietary Toll-like Receptor 3 agonis...Vaccine Congress 2008 in Lyon, France.,Study resul...juvant,targeting the Toll-like Receptor 3 (TLR3) p...
(Date:10/7/2008)...ct. 7 /- Prometheus Laboratories Inc....ced findings from its,development of PROMETHEUS(R)... irritable bowel syndrome (IBS). The findings sugg...rticular biomarkers in blood samples,between IBS a...iomarkers,combined with a proprietary algorithm, ...
(Date:10/7/2008)...s, Oct. 7 /- The Texas Cardiac Arrhyt...r has been selected as one of,only a few sites in ...cal,trial for a new device to treat persistent atr..., training and research center specializing in hea...David,s Medical Center and,Texas Cardiovascular Co...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Park Dental Announces Separation From Its Administrative Service Provider 13335 1Park Dental Announces Separation From Its Administrative Service Provider 13335 2Park Dental Announces Separation From Its Administrative Service Provider 13335 3Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 1Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 1Pump It Up and Autism Society of America Launch Bounce for Autism 13331 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 3MSU research indicates testosterone could guard against eating disorders 13329 1MSU research indicates testosterone could guard against eating disorders 13329 2
...the CDC that none of its influenza vaccine (Fluvir...ted States for the current influenza season. In th...e anticipated American vaccine supply, medical off...gly alarmed about the scarcity of vaccine and the ...e seen if virulent new strains of flu or an abnorm...
...f rapid, easy-to-use diagnostic tests, many assays...ace to help clinicians assess dosage appropriatene...ence of drugs of abuse. Some of these products req...s are suitable for point of care use by medical pr..., Therapeutic drug monitoring measures the serum ...
Other Medicine Technology:Rapid Flu Tests May Prove Especially Helpful This Season 2Rapid Flu Tests May Prove Especially Helpful This Season 3Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 2Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 3Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 4
(Date:10/11/2008)... MegaFest International Transcends Cultural D...wswire/ -- South African and,international audienc...national,s electrifying gathering, which for the f...ica., (Photo: http://www.newscom.com/cgi-bin/prn...y festival kicked off with performances by,South A...
(Date:10/10/2008)...likely to develop some form of disease by 20 years... Oct. 10 (HealthDay News) -- Liver transplant pati...neral population, say researchers in Finland. ,... Liver Transplantation , researchers investigated...splant recipients from Helsinki University Central...
(Date:10/10/2008)...Lilly and Company committed to helping people addr...re-FirstCall/ -- In these troubling,economic times...priority,and may feel that they don,t have the mon...ccording to a survey by the National Association o...t 2008:(1), -- Twenty-two percent of Americans sa...
(Date:10/10/2008)...FORD, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Hol...manufacturer and supplier of premium,diagnostics, ...cated to,serving the healthcare needs of women, to...and fiscal 2008 operating results on Tuesday, Nove...ith the release, management will,host a conference...
Breaking Medicine News(10 mins):Health News:Bishop T.D. Jakes Electrifies South Africa 2Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2
...se or survival for children and young adults with ...ancer Hospital at The University of Texas M. D. A...g leukemia patients over the past decade has shown...C), a measure of normal immune cells found on ever...
...boosted the potency of platinum-based cancer drugs... cell lines and to mice with tumors, scientists f...g a platinum chemotherapy agent and the diabetes d...e tumors as much as three times more effectively t...
...ect for countries that recently have made progress...t released on Monday by Save the Children, the Ne... the World's Mothers: Saving the Lives of Children... a mother and child in 60 developing countries whe...
...urnal of the American Medical Association, researc...of contracting lymphoma. The cancer of the immun...d to be 30 percent times higher in patients with h...denstroms macroglobulinemia, the risk of a hepatit...
Other Medicine News:Health News:Lymphocyte Count Found to Be a Predictor of Survival for Young Patients With Leukemia 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 3Health News:Family Planning Initiatives Central To Reducing Child Mortality in Developing Countries 2Health News:Hepatitis C Carries Another Risk-Cancer Of The Immune System 2
Barraquer needle holder, curved, delicate.
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Yasargil Spring Hool with Bulldog Clamp, Galea hook.
Extremely fine straight.
Medicine Products: